Morgan Stanley raised the firm’s price target on Gartner to $470 from $440 and keeps an Equal Weight rating on the shares. The firm’s AlphaWise Contract Value Estimator for Research tracker predicts Q2 FX-neutral Contract Value, or CV, growth of 4.4%, notes the analyst, who thinks the FX-neutral “bogey” for Q2 CV is likely about 6.5%-7.0% growth.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IT: